Probenecid

Evidence Level: L5

Predicted Indications: 3

Probenecid
Probenecid: From Gout and Hyperuricemia to Renal Hypouricemia

## Pharmacist Assessment Report

Using the report structure exactly as specified in your prompt. A few data-fidelity notes before the report:

drug.original_indications is empty and original_moa is [Data Gap] (DG002) — no original indication/MOA is present in the evidence pack itself. I’ve used Probenecid’s well-established pharmacological classification (uricosuric agent) only where the template’s fallback language explicitly calls for it, and flagged it clearly as outside the evidence pack.
taiwan_regulatory.licenses is empty (0 registrations, Not marketed) → per your Prohibition #5 (“do not list empty sections”), the Market Information table is omitted rather than shown empty.
Probenecid is not antineoplastic → Cytotoxicity section omitted per the rules.
key_warnings/contraindications are both [Data Gap] → excluded per Prohibition #1; only the DDI data (which has real content) is reported under Safety.
I added one short subsection (“Other Candidate Indications Considered”) that isn’t in your template’s fixed list, because omitting ranks #2 and #3 — which carry real safety signal — would violate “do not omit data.” It sits between the reasoning section and the trial/literature tables so the required section order is otherwise untouched.

Probenecid: From Gout and Hyperuricemia to Renal Hypouricemia

One-Sentence Summary

Probenecid is a classic uricosuric agent historically used to treat gout and chronic hyperuricemia by blocking renal urate reabsorption; its formal original-indication and mechanism-of-action records are not present in this evidence pack (Data Gap DG002). The TxGNN model’s top prediction is Renal Hypouricemia, scoring 99.73%, but this is backed by 0 clinical trials and 20 publications that describe the disease itself rather than treatment with probenecid — and the evidence pack’s own mechanistic rationale flags the prediction as pharmacologically inverted, not merely unproven. Combined with a Blocking-severity gap in TFDA safety labeling, the evidence supports a Hold recommendation.

Quick Overview

Item	Content
Original Indication	Gout / hyperuricemia (uricosuric agent) — not present in evidence pack; general pharmacological classification only, see Data Gap DG002
Predicted New Indication	Renal Hypouricemia (hypouricemia, renal)
TxGNN Prediction Score	99.73%
Evidence Level	L5
India Market Status	✗ Not marketed (Not Marketed)
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed DrugBank mechanism-of-action data is not available for Probenecid (Data Gap DG002). Based on the mechanistic rationale supplied alongside this prediction, Probenecid acts by inhibiting the renal tubular transporters URAT1 (SLC22A12) and OAT1/OAT3, which blocks urate reabsorption and thereby lowers serum uric acid — the pharmacological basis for its traditional use in gout/hyperuricemia.

Renal Hypouricemia is caused by the opposite problem: loss-of-function mutations in the same gene, URAT1/SLC22A12, that cause patients to already lose too much urate through the kidneys. TxGNN’s high score most likely reflects that the drug’s molecular target and the disease’s causal gene are the same knowledge-graph node (URAT1), which the model reads as a strong association — not that the drug corrects the disease.

Mechanistically, this direction is inverted: a drug that further inhibits URAT1-mediated reabsorption would be expected to worsen urinary urate loss in a condition already defined by excessive urate loss, rather than treat it. The evidence pack’s own rationale states there is “no therapeutic justification” for this pairing. This is a useful illustration of a TxGNN false-positive pattern — shared-target similarity without directional pharmacological logic — rather than a genuine repurposing signal.

Other Candidate Indications Considered (Also Hold)

Rank	Disease	TxGNN Score	Evidence Level	Trials / Literature	Key Concern
2	Lesch-Nyhan Syndrome	99.39%	L4	0 / 4 (all old, tier 3)	HGPRT deficiency causes urate overproduction; standard care is xanthine-oxidase inhibition (e.g. allopurinol), not increased excretion. A uricosuric agent risks worsening uric acid crystalluria/nephrolithiasis in this population.
3	HGPRT Partial Deficiency (Kelley-Seegmiller spectrum)	99.37%	L5	0 / 0	Same overproduction/excretion mismatch as above, but with zero supporting literature or trials — a pure graph-topology extrapolation from the Lesch-Nyhan node.

All three candidates carry a decision_stage: S0 and recommendation: Hold in the source data.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
14694169	2004	Cohort (molecular/genetic)	J Am Soc Nephrol	Sequenced SLC22A12 in 32 Japanese renal hypouricemia patients; established URAT1 loss-of-function as the causal mechanism
31650389	2020	Review	Clinical Rheumatology	Narrative review of hypouricemia etiologies for rheumatologists
16678460	2006	Review/Case report	Molecular Genetics and Metabolism	Overview of hereditary renal hypouricemia caused by SLC22A12 (URAT1) mutations
7771493	1995	Case report/Review	Am J Kidney Dis	Renal hypouricemia complicated by exercise-induced acute renal failure
8976099	1996	Review	Nihon Rinsho	Classification of urate metabolism abnormalities (hyper- and hypouricemia)
476267	1979	Review	Biomedicine	Review of inborn hypouricemia due to isolated renal tubular defect across 8 families
3813739	1987	Case report	Archives of Internal Medicine	Diabetic patients with renal hypouricemia from increased pyrazinamide-suppressible urate clearance
14655203	2003	Case report	Am J Kidney Dis	Siblings with hereditary renal hypouricemia and exercise-induced acute renal failure
1944743	1991	Case series	Nephron	Type 1 diabetic patients with renal hypouricemia and elevated urate clearance
1656732	1991	Case report	Am J Kidney Dis	Cholangiocarcinoma-associated severe renal hypouricemia

Important caveat: none of the 20 retrieved publications evaluate Probenecid as a treatment for renal hypouricemia. Several (e.g. PMID 854144, 8341392, 7099326 — not tabled above) instead use probenecid as a diagnostic challenge test: patients with URAT1 loss-of-function show a blunted uricosuric response to probenecid, which is used to characterize the transport defect, not to treat it. This reinforces that the literature volume behind this candidate does not constitute therapeutic evidence.

Safety Considerations

Drug Interactions (from DDI database; 71 total interactions on file, 20 retrieved in this query):

Major: Phenylbutyric acid, Glycerol phenylbutyrate
Moderate: Acetylsalicylic acid, Chlorpropamide, Glimepiride, Repaglinide, Nateglinide, Tolazamide, Glipizide, Glyburide, Acetohexamide, Tolbutamide
Minor: Famotidine, Amoxicillin, Eluxadoline, Levofloxacin
Unknown/unclassified: Pantoprazole, Morphine, Omeprazole, Lansoprazole

Notably, several Moderate-level interactions involve sulfonylurea antidiabetics (potential potentiation of hypoglycemic effect), and aspirin is known to antagonize probenecid’s uricosuric action pharmacodynamically.

TFDA-specific warnings and contraindications are not available in this evidence pack (Data Gap DG001, Blocking severity) — please refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale:

A Blocking-severity data gap (missing TFDA warnings/contraindications, DG001) means the safety profile cannot clear even an initial S1 review.
The top-ranked prediction (Renal Hypouricemia) is mechanistically inverted rather than merely under-evidenced — the drug’s known pharmacology works against, not toward, this indication — and has zero clinical trials.
The two lower-ranked candidates (Lesch-Nyhan Syndrome, HGPRT Partial Deficiency) share the same excretion-vs-overproduction mismatch and are supported by minimal-to-no literature or trials.
All three candidates already carry a Hold recommendation and S0 decision stage in the source scoring.

To proceed, the following is needed:

TFDA/DrugBank package insert data (warnings, contraindications) to close DG001 and DG002
A pharmacodynamic or preclinical study directly testing probenecid in a URAT1 loss-of-function (renal hypouricemia) model, rather than inferring from shared-gene association
Independent review of whether the TxGNN score reflects a genuine signal or a shared-node graph artifact, before allocating further evaluation resources to this candidate
If Lesch-Nyhan-spectrum indications are pursued further, an explicit safety assessment of uricosuric therapy risk (urolithiasis/urate nephropathy) in urate-overproduction states
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.